Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inflation, Indian Economy Drives Firms To Reduce CRAMS Work

This article was originally published in PharmAsia News

Executive Summary

Increasing prices of raw materials and India's economic condition are leading many companies providing contract research and manufacturing services to scale back their efforts. Some of the CRAMS companies are reducing their operation or writing more restrictive contracts to protect themselves against potential losses. Some industry executives expect profit margins for the CRAMS sector of the drug-making industry to fall by nearly half, from the current 6 percent to 3 percent. Plethico Pharmaceuticals of Mumbai says high inflation and the price of oil have convinced it to reduce its CRAMS business as contracts come up for renegotiation. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts